Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies

Shots:

• Sosei Heptares to receive $26M as up front and near-term payment, up to $1B as research, development and commercialization milestones and royalties on sales. Genentech to get exclusive WW rights to develop & commercialize therapies for each novel target
•  The focus of the agreement is to combine Sosei Heptares’ GPCR-focused structure-based drug design capabilities with Genentech’s discovery, development and therapeutic area expertise directed for developing multiple GPCR targets nominated by Genentech
• Sosei Heptares’ StaR technology forms the backbone of integrated SBDD platform unlocking GPCRs through an advanced understanding of their structure and delivers therapies across multiple therapeutic areas including CNS, immuno-oncology, gastroenterology & inflammation

Click here to read full press release/article | Ref: PRNewswire | Image: Glassdoor